Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Leukemia

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 70 articles:
HTML format
Text format



Single Articles


    June 2018
  1. MAUVIEUX L, Miguet L, Fornecker L
    Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
    N Engl J Med. 2018;378:2442-3.
    PubMed     Text format    


  2. ULRICH BC
    Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
    N Engl J Med. 2018;378:2442.
    PubMed     Text format    



  3. Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
    N Engl J Med. 2018;378:2442-2443.
    PubMed     Text format    


    May 2018
  4. COPUR MS, Gauchan D, Crockett D
    Venetoclax-Rituximab in Chronic Lymphocytic Leukemia.
    N Engl J Med. 2018;378:2142-3.
    PubMed     Text format    


  5. FERHANOGLU B, Ozturk E, Ozbalak M
    Venetoclax-Rituximab in Chronic Lymphocytic Leukemia.
    N Engl J Med. 2018;378:2141-2.
    PubMed     Text format    



  6. Venetoclax-Rituximab in Chronic Lymphocytic Leukemia.
    N Engl J Med. 2018;378:2141-2144.
    PubMed     Text format    


  7. RATNER L, Waldmann TA, Janakiram M, Brammer JE, et al
    Rapid Progression of Adult T-Cell Leukemia-Lymphoma after PD-1 Inhibitor Therapy.
    N Engl J Med. 2018;378:1947-1948.
    PubMed     Text format    


    April 2018
  8. KORONES DN
    The Long Ride Home.
    N Engl J Med. 2018;378:1569-1571.
    PubMed     Text format    



  9. More on Ofatumumab for TTP.
    N Engl J Med. 2018;378:1364-1365.
    PubMed     Text format    


    March 2018
  10. JONGEN-LAVRENCIC M, Grob T, Hanekamp D, Kavelaars FG, et al
    Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
    N Engl J Med. 2018;378:1189-1199.
    PubMed     Text format     Abstract available


  11. STEENSMA DP, Ebert BL
    Clonal Hematopoiesis after Induction Chemotherapy for Acute Myeloid Leukemia.
    N Engl J Med. 2018;378:1244-1245.
    PubMed     Text format    


  12. SEYMOUR JF, Kipps TJ, Eichhorst B, Hillmen P, et al
    Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
    N Engl J Med. 2018;378:1107-1120.
    PubMed     Text format     Abstract available


    February 2018
  13. EL-JAWAHRI AR, Schaefer PW, El Khoury JB, Martinez-Lage M, et al
    Case 5-2018: A 63-Year-Old Man with Confusion after Stem-Cell Transplantation.
    N Engl J Med. 2018;378:659-669.
    PubMed     Text format    


  14. PARK JH, Riviere I, Gonen M, Wang X, et al
    Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.
    N Engl J Med. 2018;378:449-459.
    PubMed     Text format     Abstract available


  15. MAUDE SL, Laetsch TW, Buechner J, Rives S, et al
    Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.
    N Engl J Med. 2018;378:439-448.
    PubMed     Text format     Abstract available


    January 2018
  16. HIBBERT KA, Shepard JO, Lane RJ, Azar MM, et al
    Case 1-2018. A 39-Year-Old Woman with Rapidly Progressive Respiratory Failure.
    N Engl J Med. 2018;378:182-190.
    PubMed     Text format    


    December 2017
  17. KORTE AKM, Vos JM
    Ecthyma Gangrenosum.
    N Engl J Med. 2017;377:e32.
    PubMed     Text format    


    November 2017
  18. SAHOO RK, Kumar L
    Midostaurin in FLT3-Mutated Acute Myeloid Leukemia.
    N Engl J Med. 2017;377:1901-2.
    PubMed     Text format    


  19. ESKAZAN AE
    Midostaurin in FLT3-Mutated Acute Myeloid Leukemia.
    N Engl J Med. 2017;377:1901.
    PubMed     Text format    



  20. Midostaurin in FLT3-Mutated Acute Myeloid Leukemia.
    N Engl J Med. 2017;377:1902.
    PubMed     Text format    


    October 2017
  21. ROSENBAUM L
    Tragedy, Perseverance, and Chance - The Story of CAR-T Therapy.
    N Engl J Med. 2017;377:1313-1315.
    PubMed     Text format    


    August 2017
  22. BRAUN R, Holler E
    Acute Ocular Graft-versus-Host Disease.
    N Engl J Med. 2017;377:676.
    PubMed     Text format    


    June 2017
  23. STONE RM, Mandrekar SJ, Sanford BL, Laumann K, et al
    Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.
    N Engl J Med. 2017 Jun 23. doi: 10.1056/NEJMoa1614359.
    PubMed     Text format     Abstract available



  24. Blinatumomab for Acute Lymphoblastic Leukemia.
    N Engl J Med. 2017;376:e49.
    PubMed     Text format    



  25. Blinatumomab for Acute Lymphoblastic Leukemia.
    N Engl J Med. 2017;376:e49.
    PubMed     Text format    


  26. SPIVAK JL
    Myeloproliferative Neoplasms.
    N Engl J Med. 2017;376:2168-2181.
    PubMed     Text format    


    May 2017
  27. GORDON SW, Krystal GW
    Auer Rods.
    N Engl J Med. 2017;376:2065.
    PubMed     Text format    


    April 2017
  28. GREMBECKA J, Cierpicki T
    Stabilizing the Mixed Lineage Leukemia Protein.
    N Engl J Med. 2017;376:1688-1689.
    PubMed     Text format    


    March 2017
  29. KHAN U, Hadid T
    Plasmacytomas and Plasma-Cell Leukemia.
    N Engl J Med. 2017;376:e19.
    PubMed     Text format    


  30. HOCHHAUS A, Larson RA, Guilhot F, Radich JP, et al
    Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
    N Engl J Med. 2017;376:917-927.
    PubMed     Text format     Abstract available


  31. LONGO DL
    Imatinib Changed Everything.
    N Engl J Med. 2017;376:982-983.
    PubMed     Text format    


  32. KANTARJIAN H, Stein A, Gokbuget N, Fielding AK, et al
    Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.
    N Engl J Med. 2017;376:836-847.
    PubMed     Text format     Abstract available


    February 2017
  33. MONTALBAN-BRAVO G, Takahashi K, Garcia-Manero G
    Decitabine in TP53-Mutated AML.
    N Engl J Med. 2017;376:796-7.
    PubMed     Text format    


  34. WELCH JS, Petti AA, Ley TJ
    Decitabine in TP53-Mutated AML.
    N Engl J Med. 2017;376:797-8.
    PubMed     Text format    


    November 2016
  35. WELCH JS, Petti AA, Miller CA, Fronick CC, et al
    TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    N Engl J Med. 2016;375:2023-2036.
    PubMed     Text format     Abstract available


  36. MORI J, Tsuda K, Tanimoto T
    Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia.
    N Engl J Med. 2016;375:2100.
    PubMed     Text format    



  37. Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia.
    N Engl J Med. 2016;375:2100-2101.
    PubMed     Text format    


  38. ESTEY E
    Acute Myeloid Leukemia - Many Diseases, Many Treatments.
    N Engl J Med. 2016;375:2094-2095.
    PubMed     Text format    


    September 2016
  39. MAURY S, Chevret S, Thomas X, Heim D, et al
    Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia.
    N Engl J Med. 2016;375:1044-53.
    PubMed     Text format     Abstract available


  40. MILANO F, Gooley T, Wood B, Woolfrey A, et al
    Cord-Blood Transplantation in Patients with Minimal Residual Disease.
    N Engl J Med. 2016;375:944-53.
    PubMed     Text format     Abstract available


  41. LEMONNIER F, Inoue S, Mak TW
    Genomic Classification in Acute Myeloid Leukemia.
    N Engl J Med. 2016;375:900-1.
    PubMed     Text format    



  42. Genomic Classification in Acute Myeloid Leukemia.
    N Engl J Med. 2016;375:900-1.
    PubMed     Text format    


    August 2016
  43. OTHUS M, Estey E, Gale RP
    Assessment of Minimal Residual Disease in Standard-Risk AML.
    N Engl J Med. 2016;375:e9.
    PubMed     Text format    


  44. MORIN-ZORMAN S, Renneville A, Ades L
    Assessment of Minimal Residual Disease in Standard-Risk AML.
    N Engl J Med. 2016;375:e9.
    PubMed     Text format    


  45. BACCARANI M
    Assessment of Minimal Residual Disease in Standard-Risk AML.
    N Engl J Med. 2016;375:e9.
    PubMed     Text format    


  46. HILLS RK, Ivey A, Grimwade D
    Assessment of Minimal Residual Disease in Standard-Risk AML.
    N Engl J Med. 2016;375:e9.
    PubMed     Text format    


    July 2016
  47. DAVIDS MS, Kim HT, Bachireddy P, Costello C, et al
    Ipilimumab for Patients with Relapse after Allogeneic Transplantation.
    N Engl J Med. 2016;375:143-53.
    PubMed     Text format     Abstract available


  48. TIBERGHIEN P, Follea G, Muller JY
    Platelet Transfusions in Acute Leukemia.
    N Engl J Med. 2016;375:96-7.
    PubMed     Text format    


    June 2016
  49. GOTLIB J, Kluin-Nelemans HC, George TI, Akin C, et al
    Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.
    N Engl J Med. 2016;374:2530-41.
    PubMed     Text format     Abstract available


  50. LORENZO ME, Carter JB, Barnes JA, Nazarian RM, et al
    CASE RECORDS of the MASSACHUSETTS GENERAL HOSPITAL. Case 19-2016. A 65-Year-Old Man with End-Stage Renal Disease and a Pruritic Rash.
    N Engl J Med. 2016;374:2478-88.
    PubMed     Text format    


  51. KANTARJIAN HM, DeAngelo DJ, Stelljes M, Martinelli G, et al
    Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
    N Engl J Med. 2016.
    PubMed     Text format     Abstract available


  52. VINY AD, Levine RL
    Roads Diverge--A Robert Frost View of Leukemia Development.
    N Engl J Med. 2016;374:2282-4.
    PubMed     Text format    


  53. PAPAEMMANUIL E, Gerstung M, Bullinger L, Gaidzik VI, et al
    Genomic Classification and Prognosis in Acute Myeloid Leukemia.
    N Engl J Med. 2016;374:2209-21.
    PubMed     Text format     Abstract available


  54. WALTER HS, Salles GA, Dyer MJ
    New Agents to Treat Chronic Lymphocytic Leukemia.
    N Engl J Med. 2016;374:2185-6.
    PubMed     Text format    


  55. ZAMAN F, Savendahl L
    New Agents to Treat Chronic Lymphocytic Leukemia.
    N Engl J Med. 2016;374:2185.
    PubMed     Text format    


  56. ROBERTS AW, Davids MS, Seymour JF
    New Agents to Treat Chronic Lymphocytic Leukemia.
    N Engl J Med. 2016;374:2186-7.
    PubMed     Text format    


    May 2016
  57. SHAPIRO MF
    Considering the Common Good--The View from Seven Miles Up.
    N Engl J Med. 2016;374:2006-7.
    PubMed     Text format    


    April 2016
  58. RUCHLEMER R, Ami RB, Lachish T
    Ibrutinib for Chronic Lymphocytic Leukemia.
    N Engl J Med. 2016;374:1592-5.
    PubMed     Text format     Abstract available


  59. RIGOLIN GM, Cavazzini F, Cuneo A
    Ibrutinib for Chronic Lymphocytic Leukemia.
    N Engl J Med. 2016;374:1592-5.
    PubMed     Text format     Abstract available


  60. SHARMAN JP, Mato AR, Keating MJ
    Ibrutinib for Chronic Lymphocytic Leukemia.
    N Engl J Med. 2016;374:1592-5.
    PubMed     Text format     Abstract available



  61. Ibrutinib for Chronic Lymphocytic Leukemia.
    N Engl J Med. 2016;374:1592-5.
    PubMed     Text format     Abstract available


    March 2016
  62. LO-COCO F, Di Donato L, Schlenk RF
    Targeted Therapy Alone for Acute Promyelocytic Leukemia.
    N Engl J Med. 2016;374:1197-8.
    PubMed     Text format    



  63. Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia; Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia; Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia.
    N Engl J Med. 2016;374:998.
    PubMed     Text format     Abstract available


  64. ARMSTRONG GT, Chen Y, Yasui Y, Leisenring W, et al
    Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer.
    N Engl J Med. 2016;374:833-42.
    PubMed     Text format     Abstract available


    February 2016
  65. IVEY A, Hills RK, Simpson MA, Jovanovic JV, et al
    Assessment of Minimal Residual Disease in Standard-Risk AML.
    N Engl J Med. 2016;374:422-33.
    PubMed     Text format     Abstract available


  66. BURKE MJ
    Minimal Residual Disease in NPM1-Mutated AML.
    N Engl J Med. 2016;374:481-2.
    PubMed     Text format    


    January 2016
  67. WILSON WH
    Progress in Chronic Lymphocytic Leukemia with Targeted Therapy.
    N Engl J Med. 2016;374:386-8.
    PubMed     Text format    


    December 2015
  68. BYRD JC, Harrington B, O'Brien S, Jones JA, et al
    Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
    N Engl J Med. 2015.
    PubMed     Text format     Abstract available


  69. ROBERTS AW, Davids MS, Pagel JM, Kahl BS, et al
    Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
    N Engl J Med. 2015.
    PubMed     Text format     Abstract available


  70. BURGER JA, Tedeschi A, Barr PM, Robak T, et al
    Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    N Engl J Med. 2015.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: